Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released positive topline data from its phase 2a clinical trial of AP-325. The trial ...
The effect of levetiracetam, an antiseizure therapy, on high-frequency oscillation in patients with Alzheimer’s disease as ...
which is nearing initiation of Phase 2 clinical trial in patients with moderate-to-severe rheumatoid arthritis, and a Phase 2a clinical trial for an additional autoimmune indication. Uvax Bio ...
According to the scientists, study participants had fewer days to recover from the illnesses when compared to the standard of ...
Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...
Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) climbed 10% following the announcement of a significant clinical response in the first patient treated with Bria-OTS, the company's novel ...
Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for ...
Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback